Josh Kaufman

Cooley advised Redx Pharma, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a $425 million and contingent value right transaction.

Cooley advised Silence Therapeutics in a $56.5 million registered direct offering of 5,950,000 American Depositary Shares (ADS), each representing three ordinary shares, at a price of $9.50 per ADS. Silence is a biotechnology company focused on discovering and developing molecules incorporating novel short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Partners Josh Kaufman, Div Gupta, Nicolas H.R. Dumont and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters on Arbor Realty Trust’s $123.9 million offering of 7,475,000 shares at $16.57 per share. Arbor Realty Trust is a national direct lender that provides debt capital for the multifamily loan and commercial real estate industries. Partners Daniel Goldberg, Josh Kaufman and Courtney M.W. Tygesson led the Cooley team.

Cooley advised IN8Bio on its $40 million initial public offering of 4,000,000 shares of common stock. IN8Bio, whose securities now trade on the Nasdaq Global Market under the symbol INAB, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell therapies. Partners Josh Kaufman, Jaime Chase and Josh Rottner led the Cooley team.

Cooley advised Sprinklr on its $292.6 million initial public offering of 18,287,500 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Sprinklr, whose securities now trade on the New York Stock Exchange under the symbol CXM, is the unified customer experience management platform for modern enterprises. Partners Nicole Brookshire, Josh Kaufman and Jaime Chase led the Cooley team.